TWD 79.1
(-1.25%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -193.47 Million TWD | -32.19% |
2022 | -146.36 Million TWD | -36.44% |
2021 | -107.27 Million TWD | -5.97% |
2020 | -101.23 Million TWD | -62.17% |
2019 | -62.42 Million TWD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q1 | -156.92 Million TWD | 18.89% |
2024 Q2 | -346.59 Million TWD | -120.87% |
2023 Q4 | -193.47 Million TWD | -28.64% |
2023 FY | -193.47 Million TWD | -32.19% |
2023 Q3 | -150.4 Million TWD | 4.07% |
2023 Q2 | -156.78 Million TWD | -96.85% |
2023 Q1 | -79.64 Million TWD | 47.76% |
2022 FY | -146.36 Million TWD | -36.44% |
2022 Q4 | -152.45 Million TWD | 0.0% |
2021 FY | -107.27 Million TWD | -5.97% |
2020 FY | -101.23 Million TWD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
DIVA Laboratories, Ltd. | -534.39 Million TWD | 63.795% |
Genetics Generation Advancement Corp. | -79.18 Million TWD | -144.343% |
Welgene Biotech Co.,Ltd. | -33.78 Million TWD | -472.708% |
Puriblood Medical Co., Ltd. | -65.84 Million TWD | -193.856% |
TFBS Bioscience Inc. | -797.57 Million TWD | 75.742% |